DoD Prostate Cancer Research Program anticipated funding opportunities for FY23

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The FY23 Defense Appropriations Act provides funding for the Prostate Cancer Research Program to support innovative, high-impact prostate cancer research. 

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In the phase III PSMAfore trial, Pluvicto (lutetium (177Lu) vipivotide tetraxetan) met its primary endpoint with a clinically meaningful and statistically significant benefit in radiographic progression-free survival in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer after treatment with androgen receptor pathway inhibitor therapy, compared to a change in ARPI1. 

Login